{'fraction_non_alphanumeric': 0.020618556701030927, 'fraction_numerical': 0.041237113402061855, 'mean_word_length': 5.068181818181818, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Calcium Antagonist PY 108-068: Demonstration of Its Efficacy in Various Types of Experimental Brain Ischemia

The protective properties of PY 108-068 against ischemic disturbances in the brain were investigated in vitro and in vivo. The calcium antagonistic effects were demonstrated on isolated, calcium- loaded arterial rings of feline cerebral arteries. Determination of brain tissue oxygenation with pO2microelectrodes showed that PY 108-068 improved oxygen supply in the cortex of cats subjected to epicere- bral arterial occlusion. In a model of cerebral vasospusm induced by autologous blood supervision, PY 108- 068 reversed the spastic state of cortical microvessels. In a chronic stroke model (microsphere embolization in rats) PY 108-068 led to a significant reduction in mortality and in the severity of neurological symptoms, whereby the peroral efficacy of the drug could be demonstrated. The efficacy of PY 108-068 in a variety of ischemic insults makes this drug a promising aid in the treatment of cerebrovascular accidents. Stroke Vol 15, No 4. 1984